Becton, Dickinson and Company (NYSE:BDX) Updates FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 14.300-14.600 for the period, compared to the consensus EPS estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded up $2.65 during mid-day trading on Wednesday, hitting $245.07. 2,061,265 shares of the company were exchanged, compared to its average volume of 2,046,401. The company has a market capitalization of $71.07 billion, a P/E ratio of 41.26, a PEG ratio of 1.80 and a beta of 0.40. The business’s 50 day simple moving average is $231.33 and its two-hundred day simple moving average is $234.02. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.70%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler lifted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the sale, the executive vice president now owns 5,544 shares in the company, valued at $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 over the last 90 days. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.